Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus

Mediators of Inflammation

Volumn 2006, Issue , 2006, Pages

  Robak, Ewa ^a   Wierzbowska, Agnieszka ^a   Chmiela, Magdalena ^b   Kulczycka, Liliana ^a   Sysa Jȩdrejowska, Anna ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE METALLOPROTEINASE 9; BIOLOGICAL MARKER; GELATINASE B; ISOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOTAL METALLOPROTEINASE 9; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645220368     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI/2006/17898     Document Type: Article

References (27)

1. D S Pisetsky, G Gilkeson, and E W St Clair, "Systemic lupus erythematosus. Diagnosis and treatment," Medical Clinics of North America, vol 81, no. 1, pp. 113-128, 1997.
2. A J Swaak, J C Nossent, and R J Smeenk, "Systemic lupus erythematosus," International Journal of Clinical & Laboratory Research, vol. 22, no. 4, pp. 190-195, 1992.
3. M Walchner, M Meurer, G Plewig, and G Messer, "Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus," International Journal of Dermatology, vol. 39, no. 5, pp. 383-388, 2000.
4. E Robak, A Wozniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak, "Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity," European Cytokine Network, vol. 12, no. 3, pp. 445-452, 2001.
5. H M Belmont, S B Abramson, and J T Lie, "Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium," Arthritis & Rheumatism, vol. 39, no. 1, pp. 9-22, 1996.
6. E Robak, A Sysa-Jedrzejowska, and T Robak, "Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus," Mediators of Inflammation, vol. 12, no. 5, pp. 293-298, 2003.
7. K L Talks and A L Harris, "Current status of antiangiogenic factors," British Journal of Haematology, vol. 109, no. 3, pp. 477-489, 2000.
8. L J McCawley and L M Matrisian, "Matrix metalloproteinases: they're not just for matrix anymore!," Current Opinion in Cell Biology, vol. 13, no. 5, pp. 534-540, 2001.
9. C Matache, M Stefanescu, C Dragomir, et al., "Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus," Journal of Autoimmunity, vol. 20, no. 4, pp. 323-331, 2003.
10. A H Baker, D R Edwards, and G Murphy, "Metalloproteinase inhibitors: biological actions and therapeutic opportunities," Journal of Cell Science, vol. 115, no. pt 19, pp. 3719-3727, 2002.
11. J F Jr Woessner, "Matrix metalloproteinases and their inhibitors in connective tissue remodeling," The FASEB Journal, vol. 5, no. 8, pp. 2145-2154, 1991.
12. E Lambert, E Dasse, B Haye, and E Petitfrere, "TIMPs as multifacial proteins," Critical Reviews in Oncology/Hematology, vol. 49, no. 3, pp. 187-198, 2004.
13. D E Gomez, D F Alonso, H Yoshiji, and U P Thorgeirsson, "Tissue inhibitors of metalloproteinases: structure, regulation and biological functions," European Journal of Cell Biology, vol. 74, no. 2, pp. 111-122, 1997.
14. L Guedez, W G Stetler-Stevenson, L Wolff, et al., "In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1," The Journal of Clinical Investigation, vol. 102, no. 11, pp. 2002-2010, 1998.
15. G S Makowski and M L Ramsby, "Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus," Molecular Pathology : MP, vol. 56, no. 4, pp. 244-247, 2003.
16. J F Muñoz-Valle, M Vázquez-Del Mercado, T García-Iglesias, et al., "T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients," Clinical and Experimental Immunology, vol. 131, no. 2, pp. 377-384, 2003.
17. C Mawrin, A Brunn, C Röcken, and J M Schröder, "Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases," Acta Neuropathologica, vol. 105, no. 4, pp. 365-372, 2003.
18. S Zucker, N Mian, M Drews, et al., "Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity," The Journal of Rheumatology, vol. 26, no. 1, pp. 78-80, 1999.
19. A Faber-Elmann, Z Sthoeger, A Tcherniack, M Dayan, and E Mozes, "Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus," Clinical and Experimental Immunology, vol. 127, no. 2, pp. 393-398, 2002.
20. E Toubi, A Kessel, G Grushko, E Sabo, M Rozenbaum, and I Rosner, "The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity," Clinical and Experimental Rheumatology, vol. 20, no. 2, pp. 221-224, 2002.
21. E M Tan, A S Cohen, J F Fries, et al., "The 1982 revised criteria for the classification of systemic lupus erythematosus," Arthritis & Rheumatism, vol. 25, no. 11, pp. 1271-1277, 1982.
22. M H Liang, S A Socher, M G Larson, and P H Schur, "Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus," Arthritis & Rheumatism, vol. 32, no. 9, pp. 1107-1118, 1989.
23. A Wierzbowska, H Urbańska-Ryś, and T Robak, "Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma," British Journal of Haematology, vol. 105, no. 2, pp. 412-419, 1999.
24. E Robak, A Wozniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak, "Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus," Lupus, vol. 11, no. 6, pp. 348-355, 2002.
25. Y Liu, M Zheng, W H Yin, and B Zhang, "Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus," Zhejiang Da Xue Xue Bao Yi Xue Ban, vol. 33, no. 4, pp. 340-343, 348, 2004.
26. M H Tayebjee, K T Tan, R J MacFadyen, and G Y Lip, "Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity," Journal of Internal Medicine, vol. 257, no. 1, pp. 110-116, 2005.
27. M H Tayebjee, G Y Lip, A D Blann, and R J MacFadyen, "Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors ol matrix metalloproteinases (TIMP)-1 and -2," Thrombosis Research, vol. 115, no. 3, pp. 205-210, 2005.